TABLE 1.
Baseline characteristics of the study population and comparison between patients with and without baseline hypercholesterolemia (HC).
| Variables | Total | NHC | HC | P value |
| (N = 137) | (N = 56) | (N = 81) | ||
| Males, n (%) | 85/137 (62.04) | 34/56 (60.71) | 51/81 (62.96) | 0.79 |
| Females, n (%) | 52/137 (37.96) | 22/56 (39.29) | 30/81 (37.04) | |
| Age (years), mean ± SD | 40.71 ± 10.41 | 40.73 ± 10.5 | 40.69 ± 10.42 | 0.982 |
| 20-60 yrs (%) | 132/137 (94.60) | 53/56 (94.64) | 79/81 (97.53) | 0.376 |
| >60 yrs (%) | 5/137 (3.60) | 3/56 (5.36) | 2/81 (2.47) | |
| BMI (kg/m2), mean ± SD | 23.73 ± 2.97 | 23.84 ± 2.92 | 23.65 ± 3.05 | 0.803 |
| Characteristics of HBV infection | ||||
| HBV DNA (Log10, IU/mL), mean ± SD | 5.6 ± 10.51 | 4.24 ± 2.03 | 4.21 ± 2.0 | 0.963 |
| Quantification of HBsAg (Log10, IU/mL), mean ± SD | 3.49 ± 0.92 | 3.51 ± 0.98 | 3.41 ± 0.86 | 0.596 |
| HBeAg positive n (%) | 73/137 (53.28) | 42/81 (51.85) | 31/56 (55.36) | 0.686 |
| HBeAg negative n (%) | 64/137 (46.72) | 39/81 (48.15) | 25/56 (44.64) | |
| Laboratory values | ||||
| Total cholesterol (mg/dL), median (IQR) | 168.56 (143.62, 189.82) | 140.12 (130.95,156.04) | 186.05 (170.81,205.35) | <0.001 |
| LDL cholesterol (mg/dL), median (IQR) | 105.16 (84.28,123.33) | 79.13 (67.74,87.14) | 120.82 (106.73,131.05) | <0.001 |
| HDL cholesterol (mg/dL), median (IQR) | 46.40 (39.82,57.99) | 44.0 (37.92,51.82) | 48.25 (41.5,58.87) | 0.051 |
| Triglycerides (mg/dL), median (IQR) | 87.71 (65.56,137.77) | 77.53 (62.02,109.86) | 101.96 (77.13,150.72) | 0.094 |
| TC/HDL-C ratio, median (IQR) | 3.56 (2.97,4.20) | 3.17 (2.64,3.55) | 3.79 (3.39,4.53) | <0.001 |
| Blood glucose (mmol/L), mean ± SD | 4.92 ± 0.84 | 4.87 ± 0.86 | 4.95 ± 0.84 | 0.619 |
| Phospheremia (mmol/l) mean ± SD | 1.59 ± 4.96 | 1.1 ± 0.33 | 1.03 ± 0.18 | 0.187 |
| AST (U/L), median (IQR) | 28 (17,38) | 29 (22,37) | 25 (15.75,46.25) | 0.702 |
| ALT (U/L), median (IQR) | 24 (20,35) | 25 (22,39) | 23 (18,30.25) | 0.597 |
| STB (umol/L) mean ± SD | 15.38 ± 6.94 | 15.97 ± 8.54 | 15.0 ± 5.67 | 0.434 |
| eGFR (mL/min) mean ± SD | 114.02 ± 12.42 | 116.3 ± 11.27 | 112.53 ± 12.97 | 0.095 |
| Scr(mL/min) mean ± SD | 78.58 ± 181 | 98.11 ± 38.92 | 65.14 ± 14.85 | 0.309 |
| Other risk factors | ||||
| Cirrhosis (%) | 16/137 (11.68) | 10/56 (17.86) | 6/81 (7.41) | 0.061 |
| Fatty liver (%) | 48/137 (35.04) | 19/56 (33.93) | 29/81 (35.80) | 0.821 |
| Hypertension (%) | 8/137 (5.84) | 1/56 (1.79) | 7/81 (8.64) | 0.19 |
| Diabetes (%) | 7/137 (5.11) | 3/56 (5.36) | 4/81 (4.94) | 1.00 |
HC, hypercholesterolemia; NHC, non-hypercholesterolemia; SD, standard deviation; IQR, interquartile range; ART, antiretroviral therapy, HDL, high density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine transaminase. Scr, Serum creatinine; eGFR, estimated glomerular filtration rate; HBsAg, hepatitis B surface antigen.